Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

Published:2021-03-06 Issue:6 Volume:60 Page:685-710
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Sturkenboom Marieke G. G.,Märtson Anne-Grete,Svensson Elin M.,Sloan Derek J.,Dooley Kelly E.,van den Elsen Simone H. J.,Denti Paolo,Peloquin Charles A.,Aarnoutse Rob E.,Alffenaar Jan-Willem C.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-021-00997-0.pdf

Reference222 articles.

1. World Health Organization (WHO). Global tuberculosis report 2019. Geneva: WHO; 2019.

2. Migliori GB, Thong PM, Akkerman O, et al. Worldwide effects of coronavirus disease pandemic on tuberculosis services, January-April 2020. Emerg Infect Dis. 2020;26:2709–12.

3. Gumbo T, Alffenaar J-WC. Pharmacokinetic/pharmacodynamic background and methods and scientific evidence base for dosing of second-line tuberculosis drugs. Clin Infect Dis. 2018;67:S267–73.

4. Veringa A, Sturkenboom MG, Dekkers BG, et al. LC-MS/MS for therapeutic drug monitoring of anti-infective drugs. Trends Anal Chem. 2016;84:34–40.

5. Alffenaar J-WC, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics and pharmacodynamics in operational research to end tuberculosis. Clin Infect Dis. 2020;70:1774–80.

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis;Journal of Clinical Tuberculosis and Other Mycobacterial Diseases;2024-08

2. Drug Exposure and Treatment Outcomes in Patients With Multidrug-Resistant Tuberculosis and Diabetes Mellitus: A Multicenter Prospective Cohort Study From China;Clinical Infectious Diseases;2024-06-24

3. Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers;European Journal of Clinical Pharmacology;2024-05-09

4. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection;Journal of Antimicrobial Chemotherapy;2024-04-25

5. Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations;Journal of Antimicrobial Chemotherapy;2024-04-06